The interferons. Mechanisms of action and clinical applications.
about
Antiangiogenic therapy with interferon alfa for neovascular age-related macular degenerationInterferon alfa therapy for age-related macular degenerationAlpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replicationTargeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon GammaInterferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutationsEvolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapyVariation in interferon sensitivity and induction among strains of eastern equine encephalitis virus.Interferon Alpha Treatment and Thyroid DysfunctionThe combined effects of high-energy shock waves and cytostatic drugs or cytokines on human bladder cancer cellsSerum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy.Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy.Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.Synthesis of DNA, rRNA, and protein by Rickettsia prowazekii growing in untreated or gamma interferon-treated mouse L929 cells.Interferon induced thyroiditis.Oromucosal Administration of Interferon to HumansInterferon-alpha-induced sarcoidosis in a patient being treated for hepatitis C.Hepatitis C and interferon induced thyroiditis.Interferon-induced cutaneous necrosis.Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B.Age-dependent levels of select immunological mediators in sera of healthy childrenInterferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblastsDurable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinomaBilateral retrobulbar optic neuropathy in the setting of interferon alpha-2a therapyStudy of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients.Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous NeoplasiaHeterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?Bioactivity determination of native and variant forms of therapeutic interferons.Management of conjunctival malignant melanoma: a review and update.Cytokine therapeutics: lessons from interferon alphaQuantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.Major depression during interferon-alpha treatment: vulnerability and prevention.A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjectsA primer on cytokines: sources, receptors, effects, and inducersHuman Papilloma Virus Infection Does Not Predict Response to Interferon Therapy in Ocular Surface Squamous Neoplasia.Coinfection of TT virus and response to interferon therapy in patients with chronic hepatitis B or C.Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120.
P2860
Q24244534-334B8D51-B577-489A-8653-897C0A0087B8Q24246549-D91B8D97-5B65-4163-BFAD-079FB9DE9BDDQ24551046-16684283-A3DB-4091-8B91-097895065B76Q26779055-7A821E15-0D7D-43AD-A29E-8F5FAC611640Q27469554-3CF704AB-62CB-438F-BF47-F4E9EE0D0ADBQ27469719-6DF8104F-9587-4593-AE7D-FA959832548AQ27470862-F8EF1002-E790-4368-A5DF-B2EC55246E89Q27483686-3A871259-7134-4638-AA0D-4324E9303A39Q30486856-8F50E1E5-BD60-4440-BA33-FE1F8717B990Q32028377-440FD5FB-FEB6-479B-9D18-310D9D7F7A55Q33338541-018B9FF4-752E-4322-B0E6-3E8DDD51A4E4Q33404188-82053115-546B-46DC-B4EE-16CA143E3888Q33573942-402B96C0-54F7-4BA8-B3A3-4F69DA65BCA2Q33599454-96CADAF8-2B5A-4099-9415-B4BFBED13AC4Q33636049-396DEADD-847D-4C59-8964-418DF8C0D5F0Q33663987-1101A59A-0EE8-4C19-8AF6-8BA53488A9ACQ33706090-79C17EA9-DB8A-42D9-A156-2EF0A511D115Q33716540-8781F17C-81D0-436E-84B9-CCED0A718F6FQ33780949-D51B7E13-4F06-4EC0-9E5F-6C8E83746E7BQ33989405-92C6BD8E-2F74-4925-8C21-0B56265C8878Q33992976-EBDFFD1E-F15F-4780-8DDC-D09226171438Q34012219-EB690F90-0971-4890-A71E-AE0310912AE8Q34096874-627A46D8-877A-4468-B9CA-D3249B500D2BQ34225588-B782F73E-0714-49FC-A843-A517EACE5667Q34249831-B283EB88-CA58-44FB-9949-F2DC95A04A9BQ34394573-511F6563-9596-4450-B881-1E98D015D0A1Q34520375-BDD39F45-CBE1-47A1-9771-285D54C352F9Q34523567-278103DB-C21D-4FD8-B06B-92BD79D2625BQ34526034-46946DE8-675E-445F-8840-AA7BA6CDD788Q34635157-21A46613-1EB6-40B7-93A5-6EB78060E13FQ34667481-36F1AA37-D4B6-4A72-8DE0-89DA2383FFA0Q35033232-856CCC36-F86C-446A-82DE-CA24FC0B644FQ35101552-A8D754A7-0E57-4A38-8067-AFA46439A29DQ35122264-FFA4C1C5-74CD-4604-BB13-36CD070C30D9Q35237145-43E64093-D0D6-4B8E-9FBD-897F74BD9690Q35286136-1B611035-9DD9-4EF2-8BC0-33FD54BD8B56Q35376246-4DC9AF80-98D8-4B4C-80F5-3FD331A7F369Q36218123-1D2F6EEC-EBBE-4D50-B764-7B22C5742DB4Q36308604-CDBB877D-F307-4BC8-9DA9-918EF3C1E4A0Q36687567-3278E06F-27A3-4B5C-9B8F-DD9D1C029ECC
P2860
The interferons. Mechanisms of action and clinical applications.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
The interferons. Mechanisms of action and clinical applications.
@ast
The interferons. Mechanisms of action and clinical applications.
@en
type
label
The interferons. Mechanisms of action and clinical applications.
@ast
The interferons. Mechanisms of action and clinical applications.
@en
prefLabel
The interferons. Mechanisms of action and clinical applications.
@ast
The interferons. Mechanisms of action and clinical applications.
@en
P2093
P1476
The interferons. Mechanisms of action and clinical applications.
@en
P2093
D H Coppenhaver
D W Niesel
G J Stanton
G R Klimpel
S K Tyring
T K Hughes
W R Fleischmann
P304
P356
10.1001/JAMA.1991.03470100067035
P407
P577
1991-09-01T00:00:00Z